A dvances in the generation of 3D tissues in vitro are improving the ability to study human neurodevelopment and disease [1] [2] [3] [4] [5] [6] [7] [8] [9][10] [11] [12] [13] [14] . Human pluripotent stem cell (hPSC)-derived 3D cultures-called organoids or spheroids-recapitulate complex developmental processes, cell-cell interactions, microenvironments, tissue architectures, and extended temporal dynamics that are inaccessible in traditional in vitro cultures 15, 16 . Several groups have developed protocols to model the coordinated rounds of cell proliferation, migration, organization, and maturation required to pattern the human cerebral cortex 1,3,17 . These pluripotent-stem-cellderived 'cortical spheroids' have been shown to generate various cortical cell types-including neural progenitors, mature neuron subtypes, and astrocytes-which self-organize into distinct cortical layers and establish functional neural networks [1] [2] [3] [4] [7] [8] [9][10] [11] [12] 17, 18 . However, although single-cell analyses of cortical spheroids have identified transcriptional profiles that suggest the presence of oligodendrocyte progenitor cells (OPCs) 7,10 , and rare oligodendrocytes have been identified in isolation 19 , so far no protocol has yielded reproducible generation and maturation of oligodendrocytes, the myelinating glia of the central nervous system (CNS) and one of three major cell types of neural origin.
expressed in oligodendrocytes in the CNS (Fig. 1c, Supplementary  Fig. 2a-c) . Oligocortical spheroids exhibited low interline and interspheroid variability in the production of MYRF-positive oligodendrocytes, which constituted 21.59% ± 4.9%, 20.53% ± 3.9%, and 18.4% ± 2.2% of total cells (mean ± s.d.; a quantification schematic is presented in Supplementary Fig. 2c ) in oligocortical spheroids derived from H7, H9, and CWRU191 cells, respectively, with n = 5 spheroids per line (Fig. 1d ). Additionally, robust induction Week 8
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Week to generate neurocortical spheroids and oligocortical spheroids were the same until week 8, after which time neurocortical spheroids were grown in basal media and oligocortical spheroids were treated with PDGF-AA and IGF-1 from days 50-60 and T3 from days 60-70. Differentiation of oligodendrocytes was assessed at week 14. Magenta, neurons; red, astrocytes; green, OPCs/oligodendrocytes. b,c, Representative fluorescence images of week 14 H7-cell-derived spheroids generated with the (b) neurocortical protocol or (c) oligocortical protocol. For each, similar results were obtained from 3 independent batches of spheroids generated from 4 separate lines. Scale bars, 50 μ m; inset in c magnified 2.5× relative to the primary image. b, Neurocortical-protocol spheroids generated neurons (neurofilament (NF)) and astrocytes (GFAP), but no oligodendrocytes (PLP1). c, Oligocortical-protocol spheroids generated neurons (neurofilament), astrocytes (GFAP), and oligodendrocytes (PLP1). Inset, oligodendrocyte morphology in the outlined region, shown at higher magnification. d, Quantification of MYRF, a nuclear marker of the oligodendrocyte lineage, in week 14 spheroids generated with the neurocortical or oligocortical protocol and treated with various combinations of PDGF-AA, IGF-1, and T3. MYRF-positive cells were counted from four planes from four or five individual spheroids (n = 4, PDGF-AA-IGF-1 or T3 treatments; n = 5, NCS and OCS) for each treatment condition from lines H7, H9, and CWRU191. Data are shown as the average ± s.d. n = 3 spheroids from the same batch were used for the externally validated cell line RUES1. e, Neuron, astrocyte, and oligodendrocyte gene expression in neurocortical and oligocortical spheroids. The heat maps represent the 100 top cell-specific transcripts for each cell type. Oligodendrocyte-and astrocyte-specific genes were upregulated in oligocortical compared with neurocortical spheroids. f, Neuron-, astrocyte-, and oligodendrocyte-specific gene expression from data in e. Box plots indicate the mean (center line) first and third quartiles (box edges), and maximum and minimum values (whiskers) . e,f, RNA-seq data from 5 spheroids for each condition. Paired nonparametric Wilcoxon matched-pairs signed-rank test was used to determine significance. FPKM, fragments per kilobase of transcript per million mapped reads. of the oligodendrocyte lineage was dependent on sequential treatment with both PDGF-AA and IGF-1 and then T3, as few MYRF-positive oligodendrocytes resulted from application of either treatment individually ( Fig. 1d ). Thus, while neurocortical patterning establishes the structural and cellular framework for oligodendrogenesis, PDGF-AA, IGF-1, and T3 are necessary for reproducible induction of OPCs and oligodendrocytes.
For further validation of the reproducibility of our approach, the protocol was replicated in an independent laboratory with an independent cell line, human embryonic stem cell line RUES1 (male) 26 , and with separate personnel and reagents. MYRF-positive cells constituted 18.36% ± 3.37% of cells in the resulting RUES-derived oligocortical spheroids ( Fig. 1d , Supplementary Fig. 2a,b) .
Lastly, we used RNA sequencing of bulk spheroids to assess how PDGF-AA-IGF-1 and T3 treatments affected the global transcription of neuron, astrocyte, and oligodendrocyte genes in oligocortical spheroids compared with expression in age-matched neurocortical spheroids. Analysis of week 14 spheroids for the expression of the 100 most specific mRNA transcripts for each cell type (defined on the basis of mouse transcriptional data from https://brainrnaseq.org 27 ) showed no significant changes in neuronal gene sets but significant upregulation of glial gene sets, in particular those of the oligodendrocyte lineage ( Fig. 1e ,f). These data show that this method for the generation of oligocortical spheroids activates a global oligodendrocyte transcriptional program but does not overtly alter the expression programs of other cell types in the spheroids, including neurons.
Oligodendrocyte maturation and myelination. After initial oligocortical patterning, spheroids can be maintained in basal media for weeks to months. We analyzed neuronal diversity and oligodendrocyte maturation at weeks 20 and 30 ( Fig. 2a ). Week 20 spheroids appeared to be relatively immature. In addition to MYRF-positive oligodendrocytes, they contained a large population of early-born deep-layer neurons marked by CTIP2 and a separate, smaller population of late-born superficial-layer neurons marked by SATB2, with MYRF-positive oligodendrocytes distributed throughout ( Fig. 2b , Supplementary Fig. 3a ). However, the neuron populations demonstrated substantial overlap, consistent with ongoing migration of younger SATB2 cells through the deep layers.
As oligodendrocytes mature, they extend cellular processes that track and myelinate adjacent axons. Although PLP1 expression was robust at as early as 14 weeks in culture, PLP1 immunofluorescence did not resolve into distinct processes until week 20 ( Fig. 2c, Supplementary Fig. 3a ). Furthermore, a subset of these processes began to express myelin basic protein (MBP; Fig. 2d ), a marker of early myelin formation, suggesting that oligodendrocyte processes were associating with neuronal axons 28 . Electron microscopy (EM) revealed concentric, but often unorganized, wrapping of human axons with multiple layers of uncompacted myelin ( Fig. 2e -g, Supplementary Fig. 3b ) at week 20. Although the unorganized nature of this early oligocortical spheroid myelin can be attributed in part to the in vitro culture environment, it does show a striking resemblance to the earliest stages of in vivo fetal myelinogenesis in both humans and chicks 29, 30 . Despite T3 treatment and extensive oligodendrocyte maturation, week 20 oligocortical spheroids also maintained a pool of SOX10-positive, MYRF-negative OPCs ( Supplementary Fig. 3c ).
At week 30, spheroids contained CTIP2-and SATB2-expressing neuron populations organized into distinct cortical layers, with a large SATB2-positive population and a smaller CTIP2-positive layer (Fig. 2h ). MYRF-positive oligodendrocytes were present both throughout these layers and as a distinct layer adjacent to CTIP2positive cells (Fig. 2h ). Additionally, oligodendrocyte processes had further resolved into distinct PLP1-positive tracts that colocalized with neurofilament-expressing neuronal axons ( Fig. 2i,j) .
EM at week 30 identified neuronal axons encircled by compact myelin (Fig. 2k ), and serial block-face imaging with 3D reconstruction revealed longitudinal wraps of myelin ensheathing the axon (Fig. 2l ). However, as of week 30 we could not identify definitive evidence of further structural organization, such as nodes of Ranvier, probably due in part to the continued immaturity and minimal coherent electrical activity of spheroid neurons (a noted issue with all current spheroid and organoid technologies).
Collectively, these results demonstrate that early myelination of human neurons by human oligodendrocytes can be generated in the context of oligocortical spheroids in as little as 20 weeks, with myelin maturation, refinement, and compaction by 30 weeks. This in vitro timing is similar to the timeline for the emergence of myelin in the latter part of the third trimester of human fetal development in utero 24 , as well as the timing of human OPC maturation and myelination after transplantation to the rodent CNS 31, 32 , which suggests the potential presence of a cell-intrinsic developmental clock for human oligodendrocyte maturation, as proposed in rodents [33] [34] [35] .
Relevance to in vivo cortical development. We next evaluated the developmental and cellular organization within our oligocortical spheroids to demonstrate relevance to in vivo human cortical development. By week 8, spheroids contained robust populations of dividing nestin-positive and SOX2-positive neural progenitors, organized into SOX2-positive ventricular-like and TBR2-positive outer subventricular-like zones ( Fig. 3a,b ). The arrangement of the SOX2-positive germinal centers was reminiscent of the ventricular zone in the cortex, although not all SOX2 populations surrounded a ventricle-like void, and many were localized to the outer surface of the spheroid. At week 9, we labeled proliferating SOX2positive cells of these germinal centers with the thymidine analog 5-bromo-2′ -deoxyuridine (BrdU) ( Fig. 3c , Supplementary Fig. 4a ) and tracked their developmental trajectories. By week 14, BrdUlabeled cells had migrated away from the germinal center, forming a population distinct from the SOX2-positive germinal zones ( Fig. 3d ,e, Supplementary Fig. 4a ). At this time point, only oligocortical spheroids contained MYRF-positive OPCs, some of which were positive for both MYRF and BrdU ( Fig. 3e , Supplementary  Fig. 4a ). MYRF colocalization with BrdU is strong evidence that these cells originated from BrdU-labeled SOX2-positive progenitors found in progenitor zones of the oligocortical spheroids.
The migration of BrdU-pulsed progenitors away from germinal centers suggests that oligocortical spheroids contain a continuum of proliferative and differentiating oligodendrocytes. To assess the global diversity of cellular composition and the spectrum of glial maturation, we carried out single-cell RNA-seq on oligocortical spheroids at week 12-an early time point just after PDGF-AA-IGF-1 and T3 treatment when all populations should be represented. Cell clustering broadly distinguished between glial and neuronal populations. The glial cluster contained early progenitors (marked by vimentin, SOX2, and nestin), OPCs (marked by SOX6), and maturing oligodendrocytes (marked by PLP1 and oligodendrocyte myelin glycoprotein) with expression of proliferative markers throughout the cluster and maturation markers defining progressively more distinct subpopulations ( Supplementary Fig. 5a ). This single-cell analysis demonstrates that distinct populations of oligodendrocytes at multiple stages of development coexist in oligocortical spheroids, similar to single-cell transcriptome data from human fetal cortex 36 ( Supplementary Fig. 5a ). This suggests that oligocortical spheroids might provide an avenue for interrogation of these largely inaccessible stages of human glial development.
Tests of promyelination drugs in spheroids.
The ability to generate human oligodendrocytes that can myelinate human axons in an in vitro system provides new opportunities to explore human myelin development, disease, and therapeutics. We first tested whether our human oligocortical spheroids recapitulate known effects of previously identified promyelination drugs. Our group and others have shown two drugs approved by the US Food and Drug Administration, clemastine and ketoconazole, to be potent stimulators of rodent oligodendrocyte generation and myelination in vitro and in vivo 37, 38 . Moreover, clemastine was recently reported to enhance remyelination in a phase 2 repurposing clinical trial in human subjects with multiple sclerosis 39, 40 . To assess the effect of these promyelination drugs on human oligodendrocyte generation, we treated oligocortical spheroids with PDGF-AA and IGF-1 from days 50-60, then with DMSO, T3, clemastine, or ketoconazole from days 60-70, and finally with basal medium for 4 weeks. Quantification of MYRF-positive oligodendrocytes at week 14 revealed that clemastine (18.7% ± 2.94%) and ketoconazole (27.61% ± 5.941%) each enhanced the production of oligodendrocytes to a similar extent as T3 (21.59% ± 4.9%) compared with production in vehicle (DMSO)-treated controls (6.345% ± 1.46%) ( Fig. 4a-e ). Remarkably, when examined by EM, ketoconazoletreated spheroids also exhibited myelination by week 14 of culture, 2 months earlier than T3-treated spheroids ( Fig. 4f,g) . These results demonstrate that clemastine and ketoconazole enhance and accelerate human oligodendrogenesis and maturation, and validate that oligocortical spheroids provide a physiological and species-relevant preclinical model for the evaluation of candidate myelin therapeutics prior to human clinical trials.
Spheroids recapitulate the pathology of a myelin disorder.
Oligocortical spheroids provide an unprecedented tissue-like, minimally manipulated system in which to study hitherto inaccessible stages of human myelin formation and the pathologic processes that lead to myelin disease. We investigated the monogenic leukodystrophy Pelizaeus-Merzbacher disease (PMD; MIM number 312080) to test whether our system can recapitulate known cellular pathology and dysfunction. PMD is a rare X-linked disease associated with defects in myelin production 41 . Hundreds of mutations in the causal gene PLP1 have been identified in patients, who present with a spectrum of severity ranging from mild motor delay and spasticity to severe hypotonia with early childhood mortality.
We previously used 2D culture 42 to generate PMD oligodendrocytes derived from iPSCs from a panel of affected male subjects 28 , and demonstrated both distinct and convergent cellular phenotypes in individuals with various mutations. Here we generated oligocortical spheroids from three iPSC lines with different PMDrelated mutations: deletion of the entire PLP1 locus, duplication of the entire PLP1 locus, and a point mutation in PLP1 (c.254T> G). Phenotypically, the respective subjects were mildly (deletion), moderately (duplication), and severely (point mutation) affected. To control for both gender and cell type of origin, we simultaneously generated spheroids from a healthy control male iPSC line derived in-house, CWRU198, that expressed MYRF (18.4% ± 2.20%) and PLP1 ( Fig. 5a ,b) to similar extents as the previously described control lines H7, H9, and CWRU191.
In oligocortical spheroids, the abundance of MYRF-positive oligodendrocytes trended with disease severity, whereas the extent of PLP1 expression correlated with genetic status (Fig. 5c-h) . The PLP1-deletion line produced abundant MYRF-positive oligodendrocytes (15.14% ± 1.96%), despite the expected absence of PLP1 ( Fig. 5c,d,m) . Conversely, the duplication line produced abundant PLP1 signal ( Fig. 5e ), despite a significant decrease in the number of MYRF-positive oligodendrocytes (11.84% ± 2.27%) compared with that in CWRU198 cells (Fig. 5f,m) . In previous 2D cultures 28 , oligodendrocytes bearing the c.254T> G point mutation showed distinct perinuclear retention of PLP1 that resolved after chemical modulation of the endoplasmic reticulum (ER) stress pathway. Oligocortical spheroids recapitulated this phenotype, demonstrating frank perinuclear retention of PLP1 ( Fig. 5g ) and the most severe reduction in the number of MYRF-positive oligodendrocytes (9.69% ± 1.82%) ( Fig. 5h,m spheroids with GSK2656157, an inhibitor of protein-kinase-R-like ER kinase 43 , improved mobilization of PLP1 away from the ER and into oligodendrocyte processes ( Fig. 5i ) and significantly increased the percentage of MYRF-positive cells (15.04% ± 1.96%) ( Fig. 5j,m) . Lastly, CRISPR correction of the point mutation to the wild-type sequence ( Supplementary Fig. 6a -c) in iPSCs prior to oligocortical spheroid generation not only restored PLP1 mobilization into oligodendrocyte processes (Fig. 5k) , but also increased the percentage of MYRF-positive oligodendrocytes (17.25% ± 3.22%) back to the levels in healthy controls (Fig. 5l,m) and enabled myelin generation by 20 weeks in culture (Fig. 5n ).
The mechanistic relationships between PMD genotypes and phenotypes have not been fully characterized. Current data suggest that the accumulation of excess (e.g., duplicated) PLP1 or aberrant/misfolded (e.g., missense mutant) PLP1 leads to ER stress, cell death, and severe patient phenotypes, whereas PLP1 deletion is better tolerated 44 , and the dichotomy between cell abundance and PLP1 expression in our oligocortical spheroids is in agreement with this hypothesis. hPSC-derived brain organoids and cortical spheroids have been used to investigate mutation-specific pathologic processes involved in neuronal disorders 2, [45] [46] [47] . Having validated our system, we can extend these efforts to a wide variety of myelin diseases and begin to explore patient-specific pathogenesis over the course of oligodendrocyte birth, maturation, myelination, and death.
Discussion
Human corticogenesis is a complex process that requires the coordinated generation, migration, and maturation of distinct cell populations. While many groups have generated oligodendrocytes through in vitro 2D cultures 31, 42 and forced aggregation of differentiating neural cells 48 , hPSC-derived cortical spheroids harness intrinsic differentiation programs to recapitulate regional organization and cortical layering present in the developing human brain. Here we demonstrated a method to induce oligodendrocyte progenitors and myelinating oligodendrocytes in cortical spheroids by exposing them to growth factors PDGF, IGF-1, and T3, while preserving the general organization and regional specification demonstrated in prior neuronal models. Further work is required to refine cortical architecture in these spheroids, but the induction of all major CNS lineages provides a new opportunity to observe and perturb human cortical development and disease. In validating our system, we demonstrated applications in genetic disease modeling and preclinical drug screening. Oligocortical spheroids could be used to study many challenging concepts, from demyelination in leukodystrophies to possible remyelination strategies for people with multiple sclerosis. With further development, this system could also be used to explore basic questions of myelin development in different neuronal classes, myelin compaction, node and internode size modulation, and single-neuron and whole-spheroid electrophysiology. Regional populations of oligodendrocytes arise, migrate, and mature at distinct times during embryogenesis. In mammals, ventrally derived oligodendrocytes are among the first populations to arise, yet they are not required for proper myelination of the cortex and are mostly replaced by later Week 9
Week cortex-derived oligodendrocytes 49 . Even compared with that of nonhuman primates, the timing and duration of human myelination is regionally distinct 50 . Human-cell-derived oligocortical spheroids provide an accessible system in which to explore these and other unique aspects of human myelin development. 
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Methods
Pluripotent stem cell lines. Healthy (CWRU191 and CWRU198) and PMD iPSCs were generated prior to this study after receipt of informed consent and approval by the Case Western Reserve University and University Hospital Institutional Review Board 28, 51 . Two human embryonic stem cell (hESC) lines from the approved NIH hESC Registry (H7, NIHhESC-10-0061; H9, NIHhESC-10-0062) were also used in these studies.
Oligocortical spheroid differentiation. Neurocortical spheroids were generated from hPSCs as previously described, with variations noted below 3 . For patterning of neurocortical spheroids, pluripotent stem cell colonies cultured on vitronectin (Gibco; A14700) were lifted with dispase (Gibco; 17105-041) at 37 °C for 10 min. Intact colonies were transferred to individual low-adherence V-bottom 96-well plates (S-Bio Prime; MS-9096VZ) in 200 μ l of spheroid starter media with 10 μ M ROCK inhibitor Y-27632 (Calbiochem; 688001), 10 μ M dorsopmorphin (Sigma; P5499), and 10 μ M SB-431542 (Sigma; S4317). Spheroid starter media was DMEM/F12 (Invitrogen; 11320-033) containing 20% KnockOut Serum (Invitrogen; 12587-010), non-essential amino acids (Invitrogen; 11140050), Glutamax (Invitrogen; 35050061), β -mercaptoethanol, and 100 U/ml penicillin-streptomycin. The same media without ROCK inhibitor was used for the next 5 d, after which the media was changed to Neurobasal-A-based spheroid media. Neurobasal-A spheroid media was Neurobasal-A medium (Invitrogen; 10888022) with B-27 serum substitute without vitamin A (Invitrogen; 12587), Glutamax (Invitrogen; 35050061), and 100 U/ml penicillin-streptomycin. From day 7 to day 25, 20 ng/ml FGF-2 (R&D Systems; 233-FB-25/CF) and 10 ng/ml EGF (R&D Systems; 236-EG-200) were added to the media. Spheroids were cultured in 96-well plates through day 25, with daily half-media changes. On day 25, spheroids were transferred to ultralow-attachment six-well plates (Corning; CLS3471) at a density of 8-10 spheroids per well and cultured thus through the remainder of the protocol. Also from this point forward, 1% Geltrex (Invitrogen; A15696-01) was added to the Neurobasal-A spheroid media. Neural differentiation was induced between days 27 and 41 by supplementation of Neurobasal-A spheroid media with 20 ng/ml BDNF (R&D Systems; 248-BD) and 20 ng/ml NT-3 (R&D Systems; 267-N). Half-media changes were performed every other day between days 17 and 41.
To generate oligocortical spheroids, beginning on day 50, we added 10 ng/ ml PDGF-AA (R&D Systems; 221-AA-050) and 10 ng/ml IGF-1 (R&D Systems; 291-G1-200) to the every-other-day media changes for 10 d. Next, on day 60, we added 40 ng/ml 3,3′ ,5-triiodothronine (T3; Sigma; ST2877) to the every-other-day media changes for 10 d. When used, small molecules were supplemented during this period. 4 μ M ketoconazole and 2 μ M clemastine were added in lieu of T3. GSK2656157 was added in addition to T3.
After day 70, spheroids were matured and maintained in Neurobasal-A spheroid media with every-other-day media changes until completion of the experiment.
Independent validation. One hESC line, RUES1, from the approved NIH hESC Registry (NIHhESC-09-0012) was used. RUES1 cells were cultured on Matrigel in mTeSR1 medium (Stemcell Technologies; 85850) and lifted with StemPro Accutase (Thermo Fisher; A1110501). Oligocortical spheroid differentiation was performed as described above, with the exception of the use of N2 supplement (Thermo Fisher; 17502048) and 25 mg/ml human insulin solution (Sigma; I9278) in place of KnockOut serum replacement for days 1-7 of the differentiation protocol.
Small molecules. 4 mM stock solution of ketoconazole (Sigma; K1003), 2 mM stock solution of clemastine fumarate (Sigma; SML0445), and 10 mM stock solution of GSK2656157 (EMD Millipore; 5046510001) were prepared, aliquoted, and stored at -20 °C. Small molecules were warmed to 37 °C for 20 min before being added to prewarmed medium. Frozen aliquots were thawed no more than twice before being discarded.
BrdU labeling. To label dividing cells in spheroids, we added BrdU to culture media at a final concentration of 3 μ g/ml on days 58 and 60. Week 9 samples were collected 4 h after BrdU administration on day 60. For lineage-tracing experiments, BrdU-labeled spheroids were collected on week 14 and processed for immunohistochemistry.
PLP1 gene editing. CRISPR-Cas9 editing of a PLP1 point mutation (c.254T> G) in iPSCs was performed by the Genome Engineering and iPSC Center at Washington University in St. Louis, using a guide RNA overlapping the mutation (sequence: CCAGCAGGCGGGCCCCATAAAGG) and a single-strand oligonucleotide with 25-nt homology arms surrounding the mutation. Upon receipt, we resequenced the mutation and correction locus and karyotyped both lines in-house to ensure that no gross genotypic aberrations were generated during the editing process (Cell Line Genetics).
Immunocytochemistry. Spheroids for immunohistochemistry were initially fixed with 4% ice-cold paraformaldehyde for 45 min, washed three times in PBS, and equilibrated with 30% sucrose overnight. The spheroids were embedded in OCT and sectioned at 10 μ m. Immunohistochemistry was performed as described previously 52 . Briefly, sections were washed in PBS three times and then blocked for 30 min in PBS containing 0.1% Triton X-100 and 0.25% normal donkey serum. The sections were then incubated at 4 °C overnight with primary antibodies in blocking solution. We used the following primary antibodies: rat anti-PLP1 (1:500; AA3; gift from Wendy Macklin), rabbit anti-MYRF (1:1,000; provided by Michael Wegner), goat anti-SOX10 (1:250; R&D Systems; AF 2864), rabbit anti-OLIG2 (1:250; Millipore; AB9610), mouse anti-pan-axonal neurofilament (1:1,000, Covance; SMI311), mouse anti-MBP (1:200; Covance; Smi99), mouse anti-pan-neuronal neurofilament (NF; 1:1,000; Covance; SMI312), rabbit anti-GFAP (1:1,000; Dako; Z0334), mouse anti-SATB2 (1:250; Abcam; ab51520), rat anti-CTIP2 (1:400; Abcam; ab18465), goat anti-SOX2 (1:250; R&D Systems; AF2018), rabbit anti-TBR2 (1:250; Abcam; ab23345), mouse anti-Ki67 (1:250; Millipore; MAB4190), mouse anti-nestin (1:1,000; Millipore; MAB5326), mouse anti-BrdU (1:1,000; Millipore; MAB3510), chicken anti-vimentin (1:1,000; Abcam; ab24525); and DAPI (1 μ g/ml; Sigma; D8417). Sections were then washed in PBS and incubated in secondary antibodies for 2 h. All secondary antibodies were Life Technologies Alexa Fluor-conjugated secondary antibodies used at a dilution of 1:500. In the case of PLP1 immunohistochemistry, a 20-min wash in PBS containing 10% Triton X-100 was applied before the blocking step. In the case of MBP immunohistochemistry, we applied a 20-min post-fixation step using ice-cold acetone. After antigen retrieval we performed BrdU immunohistochemistry, which entailed placing slides in a sealed Coplin jar with boiling 100 mM sodium citrate buffer and allowing it to come to room temperature over the course of 1 h.
Spheroid sections were imaged with either a Leica DMi8 fluorescence microscope or a Leica Sp8 confocal microscope at the Case Western Reserve School of Medicine Imaging Core. For counting of MYRF-positive nuclei, four 20× fields were imaged per spheroid. Two fields from the top and bottom of the spheroid and two fields from the edges of the central region of the spheroids were quantified (see Supplementary Fig. 1c for a schematic). The total numbers of DAPI-positive cells and MYRF-positive cells were manually counted in Adobe Photoshop or NIH ImageJ. Three to five spheroids were analyzed per line and treatment condition, and GraphPad Prism was used to perform a t-test to assess statistically significant differences between lines or treatments.
Electron microscopy. Spheroids were fixed and processed as previously described 52 . Samples were fixed for 1 h at room temperature in a fixative solution containing 4% paraformaldehyde (EMS), 2% glutaraldehyde (EMS), and 0.1 M Nacacodylate (EMS). Samples were then osmicated, stained with uranyl acetate, and embedded in EMbed 812 (EMS). Ultrathin sections (120 nm) from each spheroid sample were observed with an FEI Helios NanoLab 660 FIBSEM field emission scanning electron microscope using extreme high resolution and equipped with a concentric (insertable) higher-energy electron detector. All images were taken using 4 kV and 0.2 current landing voltage at high magnification (15,000-35,000× ).
Serial block-face imaging and 3D reconstruction. Epoxy-embedded spheroids were trimmed, mounted on silicon wafers, and covered with conductive silver paint. Using a sputter coating (Cressington Scientific Instruments), we deposited an additional ~1-nm iridium layer, and then we loaded samples into a Helios Nanolab 660i dual-beam microscope (FEI Company) for imaging. After the ion column and beam coincidence had been set up at the eucentric height (tilt, 52°), for the electron beam, 2 kV and 40 pA current landing were used, then ion beam (Ga+ )-assisted platinum was deposited as a protective layer for subsequent milling for cross-sections using low current (0.23 nA), while surplus block material was removed with a high ion beam current (30 kV, 6.5 nA). For final surface polishing/ milling, we used a reduced ion current (30 kV, 2.8 nA). For imaging, the Auto Slice and View G3 software (FEI Company) was used with an electron beam current of 400 pA and horizontal field width of 11.84 μ m to acquire an image stack of 154 sections (pixel size, 1.97; z = 50 nm) using a through-the-lens detector, with a resolution of 6,144 × 4,096, dwell time of 6 μ s, and working distance of 4.04 mm. Raw images were aligned in the Fiji image processing package, and Imaris 9.1 software (Bitplane AG) was used for image visualization and 3D reconstruction of myelin bundles.
Bulk RNA sequencing and analysis. Four spheroids per line were collected in TriReagent (Zymo Research; R2050-1-200), and RNA was extracted per the manufacturer's instructions. RNA was further purified with a Qiagen RNeasy Plus mini kit (Qiagen; 73404). Illumina libraries were prepared and sequenced in 50-bp paired-end mode on a HiSeq 2500 instrument at the CWRU Genomics Core facility. Reads were aligned to the hg19 genome with TopHat v2.0.6 without a reference transcriptome 53 . The abundance of transcripts from the iGenomes hg19 RefSeq reference was measured with Cufflinks v2.0.2 54 . FPKM values (fragments per kilobase of transcript per million mapped reads) were quantilenormalized. Neuron-, astrocyte-, and oligodendrocyte-specific genes were defined by expression (FPKM > 1) in their respective cells and absence in the other two lineages 27 . Each list was reduced to the 100 genes most specific to that cell type by fold change that were also detected in at least one spheroid sample. Differences in expression among gene lists were assessed by Wilcoxon test in GraphPad Prism. Corresponding author(s): Paul Tesar Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical test was used to predetermine sample size. n= 4 or 5 spheroids were used per group per treatment in order to be able to perform statistical tests.
Data exclusions
Describe any data exclusions.
No data was excluded from any experiments presented in the paper
Replication
Describe the measures taken to verify the reproducibility of the experimental findings. Spheroids were grown from 2 hES cell lines as well as 2 hiPS cell lines to establish this protocol and these results were reproduced with two additional batches from each of these lines. Additionally, this method was independently replicated in the Fossati lab.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Spheroids were generated in bulk until day 50 at which time they were randomly assigned to treatment groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Spheroid treatment experiments were not blinded since initial variations in treatment were performed to optimize a method and not to test a hypothesis. To verify the robustness of the method, downstream analysis such as EM were blinded. Samples for EM were blinded to experimenters performing imaging and analysis. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
